The difficulty is structural, not a failure of effort. Female hormonal contraception prevents one event per cycle. Male hormonal contraception has to suppress an ongoing production process to near zero and hold it there indefinitely — and the threshold for "low enough" is very low.
The mechanism available is the same one that makes testosterone therapy a fertility problem. Both testosterone replacement and anabolic-androgenic steroid use suppress the hypothalamic-pituitary-gonadal axis, resulting in diminution of spermatogenesis.[1] Male hormonal contraception is that side effect, deliberately maximised.
Why suppression has to be near-total
A single ejaculate normally contains tens of millions of sperm. Reducing that by 90% still leaves millions. Contraceptive efficacy requires driving production to azoospermia or close to it, consistently, in essentially everyone taking the drug.
Compare the female target: prevent one ovulation per cycle. Binary, monthly, and verifiable.
That asymmetry is the whole problem, and no amount of pharmaceutical investment changes it.
The second problem: replacing what you suppress
Suppressing the HPG axis to stop sperm production also stops the testes producing testosterone. A man on that regimen would be hypogonadal — with the symptoms and long-term consequences that carries.
So a male hormonal contraceptive has to do two things at once: suppress spermatogenesis, and maintain systemic androgen levels. That is why every serious candidate is an androgen, or an androgen combined with a progestin, rather than a simple blocker.
The third problem: the bar for acceptable risk
Contraception is given to healthy people. That sets the tolerable side-effect threshold far lower than for a treatment given to sick ones — and it is the reason candidates have failed on tolerability rather than efficacy.
The Cochrane review of steroid hormones for contraception in men is the systematic assessment of what the trials found.[3] Reading it against the fact that no product reached market is the most efficient summary of the field's history.
Why testosterone therapy is not contraception
An important safety point, and it follows directly.
TRT suppresses spermatogenesis, but not reliably or completely enough to prevent pregnancy.[1] It must never be used as contraception. It is also why fertility plans are first on the Endocrine Society's list of conditions under which testosterone therapy should not be started.[4]
The clinical version of that conversation is in TRT and fertility.
Frequently asked questions
Why is there a female pill and no male pill? Because interrupting one monthly event is a fundamentally easier pharmacological target than suppressing continuous production to near zero while maintaining androgen levels.
Has hormonal male contraception been shown to work? The randomised evidence is assessed systematically in the Cochrane review.[3] Efficacy has generally been less of an obstacle than tolerability and delivery.
Is my TRT protecting me from fathering a child? No. Never rely on it.[1]
Next in this series
The efficacy question was tested at scale in the 1990s, and the results are the reason the field kept going.
Continue with the WHO testosterone trials.
Treatment options for low testosterone
Low testosterone is treated with testosterone replacement therapy, prescribed and monitored by a licensed provider. It is not a single product. Testosterone replacement therapy is delivered as intramuscular or subcutaneous injections, topical gels and creams, transdermal patches, implanted pellets, and topical sprays.
Which form fits a given patient depends on dosing schedule, application routine, monitoring requirements and clinical history. That is a decision for a provider who has seen your lab work — not something to settle from an article, including this one. Testing establishes whether treatment is appropriate; it is the first step of treatment, not an alternative to it.
Keen prescribes testosterone replacement therapy as a once-daily topical transdermal spray, with at-home lab testing and ongoing physician oversight, in 30 states. Eligibility is assessed by a US-licensed physician from your labs and medical history.
References
4 sources- McBride JA, Coward RM. Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian J Androl. 2016;18(3):373–380. doi:10.4103/1008-682X.173938 · PMID 26908067
- Nieschlag E, Nieschlag S. ENDOCRINE HISTORY: The history of discovery, synthesis and development of testosterone for clinical use. Eur J Endocrinol. 2019;180(6):R201–R212. doi:10.1530/EJE-19-0071 · PMID 30959485
- Grimes DA, Lopez LM, Gallo MF, et al. Steroid hormones for contraception in men. Cochrane Database Syst Rev. 2012;2012(3):CD004316. doi:10.1002/14651858.CD004316.pub4 · PMID 22419294
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364
Practical questions about membership, labs and using the spray are answered in the Learn Hub FAQ.